Your browser doesn't support javascript.
loading
Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer.
Smyth, Lillian M; Piha-Paul, Sarina A; Won, Helen H; Schram, Alison M; Saura, Cristina; Loi, Sherene; Lu, Janice; Shapiro, Geoffrey I; Juric, Dejan; Mayer, Ingrid A; Arteaga, Carlos L; de la Fuente, Macarena I; Brufksy, Adam M; Spanggaard, Iben; Mau-Sørensen, Morten; Arnedos, Monica; Moreno, Victor; Boni, Valentina; Sohn, Joohyuk; Schwartzberg, Lee S; Gonzàlez-Farré, Xavier; Cervantes, Andrés; Bidard, François-Clement; Gorelick, Alexander N; Lanman, Richard B; Nagy, Rebecca J; Ulaner, Gary A; Chandarlapaty, Sarat; Jhaveri, Komal; Gavrila, Elena I; Zimel, Catherine; Selcuklu, S Duygu; Melcer, Myra; Samoila, Aliaksandra; Cai, Yanyan; Scaltriti, Maurizio; Mann, Grace; Xu, Feng; Eli, Lisa D; Dujka, Melanie; Lalani, Alshad S; Bryce, Richard; Baselga, José; Taylor, Barry S; Solit, David B; Meric-Bernstam, Funda; Hyman, David M.
Afiliação
  • Smyth LM; Memorial Sloan Kettering Cancer Center, New York, New York.
  • Piha-Paul SA; St. Vincent's University Hospital, Dublin, Ireland.
  • Won HH; The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Schram AM; Memorial Sloan Kettering Cancer Center, New York, New York.
  • Saura C; Memorial Sloan Kettering Cancer Center, New York, New York.
  • Loi S; Vall d'Hebron University Hospital, Vall d'Hebrón Institute of Oncology (VHIO), Barcelona, Spain.
  • Lu J; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Shapiro GI; University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California.
  • Juric D; Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Mayer IA; Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Arteaga CL; Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.
  • de la Fuente MI; The University of Texas Southwestern Medical Center Harold C. Simmons Comprehensive Cancer Center, Dallas, Texas.
  • Brufksy AM; Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida.
  • Spanggaard I; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, Pennsylvania.
  • Mau-Sørensen M; Rigshospitalet University Hospital, Copenhagen, Denmark.
  • Arnedos M; Rigshospitalet University Hospital, Copenhagen, Denmark.
  • Moreno V; Institut Gustave Roussy, Paris, France.
  • Boni V; START Madrid Fundación Jimenez Diaz, Madrid, Spain.
  • Sohn J; START Madrid Hospital Universitario HM Sanchinarro, Madrid, Spain.
  • Schwartzberg LS; Yonsei Cancer Center, University College of Medicine, Seoul, Korea.
  • Gonzàlez-Farré X; West Cancer Center, University of Tennessee, Memphis, Tennessee.
  • Cervantes A; Hospital Universitari Quirón Dexeus, Barcelona, Spain.
  • Bidard FC; CIBERONC, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain.
  • Gorelick AN; Institut Curie, Paris, France.
  • Lanman RB; Memorial Sloan Kettering Cancer Center, New York, New York.
  • Nagy RJ; Guardant Health, Redwood City, California.
  • Ulaner GA; Guardant Health, Redwood City, California.
  • Chandarlapaty S; Memorial Sloan Kettering Cancer Center, New York, New York.
  • Jhaveri K; Memorial Sloan Kettering Cancer Center, New York, New York.
  • Gavrila EI; Memorial Sloan Kettering Cancer Center, New York, New York.
  • Zimel C; Memorial Sloan Kettering Cancer Center, New York, New York.
  • Selcuklu SD; Memorial Sloan Kettering Cancer Center, New York, New York.
  • Melcer M; Memorial Sloan Kettering Cancer Center, New York, New York.
  • Samoila A; Memorial Sloan Kettering Cancer Center, New York, New York.
  • Cai Y; Memorial Sloan Kettering Cancer Center, New York, New York.
  • Scaltriti M; Memorial Sloan Kettering Cancer Center, New York, New York.
  • Mann G; Memorial Sloan Kettering Cancer Center, New York, New York.
  • Xu F; Puma Biotechnology, Inc., Los Angeles, California.
  • Eli LD; Puma Biotechnology, Inc., Los Angeles, California.
  • Dujka M; Puma Biotechnology, Inc., Los Angeles, California.
  • Lalani AS; Puma Biotechnology, Inc., Los Angeles, California.
  • Bryce R; Puma Biotechnology, Inc., Los Angeles, California.
  • Baselga J; Puma Biotechnology, Inc., Los Angeles, California.
  • Taylor BS; Memorial Sloan Kettering Cancer Center, New York, New York.
  • Solit DB; Memorial Sloan Kettering Cancer Center, New York, New York.
  • Meric-Bernstam F; Memorial Sloan Kettering Cancer Center, New York, New York.
  • Hyman DM; The University of Texas MD Anderson Cancer Center, Houston, Texas.
Cancer Discov ; 10(2): 198-213, 2020 02.
Article em En | MEDLINE | ID: mdl-31806627
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Receptores de Estrogênio / Receptor ErbB-2 / Neoplasias da Mama Masculina Tipo de estudo: Clinical_trials / Observational_studies / Risk_factors_studies Limite: Aged80 Idioma: En Revista: Cancer Discov Ano de publicação: 2020 Tipo de documento: Article País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Receptores de Estrogênio / Receptor ErbB-2 / Neoplasias da Mama Masculina Tipo de estudo: Clinical_trials / Observational_studies / Risk_factors_studies Limite: Aged80 Idioma: En Revista: Cancer Discov Ano de publicação: 2020 Tipo de documento: Article País de publicação: Estados Unidos